RT Journal Article
T1 The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer
A1 Toledano-Fonseca, Marta
A1 Cano, M Teresa
A1 Inga, Elizabeth
A1 Gómez-España, Auxiliadora
A1 Guil-Luna, Silvia
A1 García-Ortiz, María Victoria
A1 Mena-Osuna, Rafael
A1 De la Haba-Rodriguez, Juan R.
A1 Rodríguez-Ariza, Antonio
A1 Aranda, Enrique
K1 NLR
K1 PLR
K1 Circulating tumor DNA
K1 Pancreatic ductal adenocarcinoma
K1 RAS mutation
K1 Neutrophil elastase
K1 Neutrofilos
K1 Linfocitos
K1 Plaquetas
K1 ADN tumoral circulante
K1 Carcinoma ductal pancreático
K1 Proteínas ras
K1 Elastasa de leucocito
AB Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvironment and liquid biopsy has emerged as a promising tool for the noninvasive analysis of this tumor. In this study, plasma was obtained from 58 metastatic PDAC patients, and neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), circulating cell-free DNA (cfDNA) concentration, and circulating RAS mutation were determined. We found that NLR was significantly associated with both overall survival (OS) and progression-free survival. Remarkably, NLR was an independent risk factor for poor OS. Moreover, NLR and PLR positively correlated, and combination of both inflammatory markers significantly improved the prognostic stratification of metastatic PDAC patients. NLR also showed a positive correlation with cfDNA levels and RAS mutant allelic fraction (MAF). Besides, we found that neutrophil activation contributed to cfDNA content in the plasma of metastatic PDAC patients. Finally, a multi-parameter prognosis model was designed by combining NLR, PLR, cfDNA levels, RAS mutation, RAS MAF, and CA19-9, which performs as a promising tool to predict the prognosis of metastatic PDAC patients. In conclusion, our study supports the idea that the use of systemic inflammatory markers along with circulating tumor-specific markers may constitute a valuable tool for the clinical management of metastatic PDAC patients.
PB MDPI
YR 2021
FD 2021-03-10
LK http://hdl.handle.net/10668/4427
UL http://hdl.handle.net/10668/4427
LA en
NO Toledano-Fonseca M, Cano MT, Inga E, Gómez-España A, Guil-Luna S, García-Ortiz MV, et al. The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer. Cancers. 2021 Mar 10;13(6):1210
DS RISalud
RD Apr 9, 2025